Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

ClinicalTrials.gov ID: NCT01763827

Public ClinicalTrials.gov record NCT01763827. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Randomized, Placebo and Ezetimibe-controlled, Multicenter Study to Evaluate Safety and Efficacy of Lipid Lowering Monotherapy With AMG 145 in Subjects With a 10-Year Framingham Risk Score of 10% or Less

Study identification

NCT ID
NCT01763827
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Amgen
Industry
Enrollment
615 participants

Conditions and interventions

Conditions

Interventions

  • Evolocumab Biological
  • Ezetimibe Drug
  • Placebo to Evolocumab Biological
  • Placebo to Ezetimibe Other

Biological · Drug · Other

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 20, 2013
Primary completion
Oct 9, 2013
Completion
Oct 28, 2013
Last update posted
Nov 7, 2022

2013

United States locations

U.S. sites
47
U.S. states
28
U.S. cities
43
Facility City State ZIP Site status
Research Site Birmingham Alabama 35216
Research Site Chandler Arizona 85224
Research Site Little Rock Arkansas 72205
Research Site Carmichael California 95608
Research Site Encinitas California 92024
Research Site San Diego California 92111
Research Site Tustin California 92780
Research Site Jacksonville Florida 32204
Research Site Jacksonville Florida 32216
Research Site Miami Florida 33144
Research Site Ponte Vedra Florida 32081
Research Site Sanford Florida 32771
Research Site Boise Idaho 83704
Research Site Chicago Illinois 60654
Research Site Indianapolis Indiana 46260
Research Site Overland Park Kansas 66202
Research Site Louisville Kentucky 40213
Research Site Bethesda Maryland 20817
Research Site Brockton Massachusetts 02301
Research Site Edina Minnesota 55435
Research Site Olive Branch Mississippi 38654
Research Site Las Vegas Nevada 89148
Research Site Endwell New York 13760
Research Site New Windsor New York 12553
Research Site Raleigh North Carolina 27609
Research Site Raleigh North Carolina 27612
Research Site Fargo North Dakota 58103
Research Site Akron Ohio 44311
Research Site Cincinnati Ohio 45212
Research Site Cincinnati Ohio 45236
Research Site Cincinnati Ohio 45246
Research Site Cleveland Ohio 44122
Research Site Norman Oklahoma 73069
Research Site Oklahoma City Oklahoma 73103
Research Site Duncansville Pennsylvania 16635
Research Site Anderson South Carolina 29621
Research Site Mt. Pleasant South Carolina 29464
Research Site Rapid City South Dakota 57702
Research Site Jackson Tennessee 38305
Research Site Boerne Texas 78006
Research Site Dallas Texas 75230
Research Site San Antonio Texas 78205
Research Site Salt Lake City Utah 84124
Research Site Norfolk Virginia 23502
Research Site Richmond Virginia 23294
Research Site Renton Washington 98057
Research Site Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01763827, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 7, 2022 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01763827 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →